First-In-Class Therapeutics to Treat Cancer
BiPER Therapeutics is a biotech company founded in 2021 to develop and commercialize novel therapeutics.
We are developing a first-in-class pipeline of small molecules targeting the metabolism of cancer cells to treat advanced cancers with high unmet medical needs
BiPER ‘s name summarizes the original and unique approach of our Lead candidate targeting BiP and leading to cancer cell death through unresloved ER (Endoplasmic Reticulum) Stress induction
BiPER has an internationally recognized team of Directors and Advisors with a strong track record in Drug Discovery, Drug Development and Translational Research in Oncology associated with a solid experience in Biotech business and corporate development.
INVESTORS & PARTNERSHIP
Interested investors, pharma companies and academics are encouraged to connect with us
Potential investors, partners and collaborators interested in the opportunity of BiPER Therapeutics?
Feel free to contact us